MYNDSET MVP Pilot Study 2022

MYND Therapeutics completed an 8-week minimum viable product (MVP) pilot study in 2022, evaluating the MYNDSET digital therapeutic platform with overweight and obese women.

The study delivered cognitive behavioral therapy (CBT) through an immersive VR/AR experience, combining educational content with interactive exercises designed to build healthier habits and reshape attitudes toward food and physical activity.

Results from the pilot were encouraging. Over 80% of participants rated the app as easy to use, indicating strong usability and engagement. More than 60% of participants reported weight loss during the 8-week period, demonstrating the potential for MYNDSET to deliver meaningful clinical outcomes.

Participants highlighted the gamified approach and immersive content as key differentiators compared to traditional weight management programs. The study provided critical validation for the MYNDSET platform and informed the next phase of product development.

These results position MYND Therapeutics to pursue larger clinical trials and seek regulatory pathways for their digital therapeutic approach to obesity management.